Ionis Pharmaceuticals IONS Ionis Operations — Drug Discovery Expenses

Similar metrics at other companies

AGPUDrug Discovery Services — Operating Income

-$978.38K-12.8%

EXELReportable Segment — Drug discovery

$18.25M-14.5%

SDGRDrug Discovery — Gross Profit

$7.51M+653%

SDGRDrug Discovery — Drug discovery services revenue from contracts with customers

$23.42M+64.8%

SDGRDrug discovery — Deferred Revenue

$48.32M+2.3%

SDGRDrug discovery — Total backlog

$8.6M—

FAQ

What is Ionis Pharmaceuticals's ionis operations — drug discovery expenses?

Ionis Pharmaceuticals (IONS) reported ionis operations — drug discovery expenses of $29.12M in Q2 2026.

How has Ionis Pharmaceuticals's ionis operations — drug discovery expenses changed year-over-year?

Ionis Pharmaceuticals's ionis operations — drug discovery expenses decreased by 3.8% year-over-year, from $30.26M to $29.12M.

What is the long-term trend for Ionis Pharmaceuticals's ionis operations — drug discovery expenses?

Over 3 years (2022 to 2025), Ionis Pharmaceuticals's ionis operations — drug discovery expenses has grown at a -11.6% compound annual growth rate (CAGR), from $181.3M to $125.16M.

What does ionis operations — drug discovery expenses mean?

These are the costs associated with early-stage research activities aimed at identifying new drug candidates and validating biological targets. This investment reflects the company's commitment to replenishing its long-term pipeline through internal innovation.